| Literature DB >> 12742586 |
Evelina Angov1, Barbara M Aufiero, Ann Marie Turgeon, Michel Van Handenhove, Christian F Ockenhouse, Kent E Kester, Douglas S Walsh, Jana S McBride, Marie-Claude Dubois, Joe Cohen, J David Haynes, Kenneth H Eckels, D Gray Heppner, W Ripley Ballou, Carter L Diggs, Jeffrey A Lyon.
Abstract
Merozoite Surface Protein-1(42) (MSP-1(42)) is a leading vaccine candidate against erythrocytic malaria parasites. We cloned and expressed Plasmodium falciparum MSP-1(42) (3D7 clone) in Escherichia coli. The antigen was purified to greater than 95% homogeneity by using nickel-, Q- and carboxy-methyl (CM)-substituted resins. The final product, designated Falciparum Merozoite Protein-1 (FMP1), had endotoxin levels significantly lower than FDA standards. It was structurally correct based on binding conformation-dependent mAbs, and was stable. Functional antibodies from rabbits vaccinated with FMP1 in Freund's adjuvant inhibited parasite growth in vitro and also inhibited secondary processing of MSP-1(42). FMP1 formulated with GlaxoSmithKline Biologicals (GSK) adjuvant, AS02A or alum was safe and immunogenic in rhesus (Macaca mulatta) monkeys.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12742586 DOI： 10.1016/s0166-6851(03)00077-x
Source DB: PubMed Journal: Mol Biochem Parasitol ISSN： 0166-6851 Impact factor: 1.759